Nexavar (sorafenib) — Medica
Acute myeloid leukemia (FLT3-ITD mutation-positive)
Initial criteria
- age ≥ 18 years
- FLT3-ITD mutation-positive disease
- used in combination with azacitidine or decitabine OR post-allogeneic stem cell transplant and in remission
Approval duration
1 year